In the BioHarmony Drug Report Database

"Preview" Icon

Tisagenlecleucel

Kymriah (tisagenlecleucel) is a cell pharmaceutical. Tisagenlecleucel was first approved as Kymriah on 2018-08-22. It has been approved in Europe to treat large b-cell lymphoma diffuse and precursor b-cell lymphoblastic leukemia-lymphoma.

 

Trade Name

 

Kymriah
 

Common Name

 

tisagenlecleucel
 

ChEMBL ID

 

CHEMBL3301574
 

Indication

 

large b-cell lymphoma diffuse, precursor b-cell lymphoblastic leukemia-lymphoma
 

Drug Class

 

Image (chem structure or protein)

Tisagenlecleucel structure rendering